<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00427180</url>
  </required_header>
  <id_info>
    <org_study_id>SP-80-00-00-00-01-V01</org_study_id>
    <secondary_id>SP-80-00-00-00-02-V01</secondary_id>
    <secondary_id>SP-80-00-00-00-03-V01</secondary_id>
    <nct_id>NCT00427180</nct_id>
  </id_info>
  <brief_title>IRIS PILOT - Extended Pilot Study With a Retinal Implant System</brief_title>
  <official_title>Extended Pilot Study to Evaluate Pattern Recognition With a Chronic Retinal Implant System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intelligent Medical Implants GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intelligent Medical Implants GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigate whether blind subjects that fulfil the patient criteria provided with a Retinal&#xD;
      Implant are able to differentiate between simple patterns like horizontal bar, vertical bar&#xD;
      and cross.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Retinal Implant System consists of three main components, the Retinal Stimulator, which&#xD;
      is the component actually implanted into the eye, the visual interface, and the Pocket&#xD;
      Processor The Retinal Stimulator will be implanted into the eye of a blind subject during a&#xD;
      surgical operation. However, the external components are activated only during the test&#xD;
      sessions under the control of the investigator team. In a first step of the investigation a&#xD;
      software controlled system on a PC which is connected to the Pocket Processor via Ethernet&#xD;
      interface, will generate the defined stimulation patterns (bars, crosses, cubes). During the&#xD;
      test session, the blind subject is exposed to a series of these stimulation patterns and he /&#xD;
      she has to describe the visual perceptions. Based on his descriptions and in an interactive&#xD;
      way, the stimulation signal is subsequently be modulated by changing parameters like&#xD;
      amplitude, duration of impulse, polarity, number of repetitions or pulse frequency on the PC.&#xD;
&#xD;
      In a second step the visual interface is equipped with a camera which presents realtime&#xD;
      images to the subject. Data obtained from the investigation with computer generated patterns&#xD;
      in the first step are used in the second step to improve the fitting software for the use in&#xD;
      the camera supported system.&#xD;
&#xD;
      Finally the system should enable the subject to recognize simple images supported from the&#xD;
      camera.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>December 2006</start_date>
  <completion_date type="Anticipated">December 2010</completion_date>
  <primary_completion_date type="Anticipated">November 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Investigate whether blind subjects that fulfill the patient criteria provided with a Retinal Implant are able to differentiate between simple patterns like horizontal bar, vertical bar and cross.</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary goals of this study phase are: Further evaluation of stimulation parameters, Light localization with use of camera, Safety verification of stimulation parameters</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Retinitis Pigmentosa</condition>
  <condition>Cone-Rod Dystrophy</condition>
  <condition>Choroideremia</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Retinal Implant System (IRIS)</intervention_name>
    <description>AIMD - Active Implantable Medical Device designed for artificial electrical neural stimulation of photoreceptor degenerated retina</description>
    <other_name>IRIS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Age between 30 and 79 years at the date of enrollment&#xD;
&#xD;
          -  Normal hearing and linguistic understanding (with hearing aids if - necessary and in&#xD;
             the language of the hospital or in English)&#xD;
&#xD;
          -  Ability to understand the study and procedures involved&#xD;
&#xD;
          -  Willingness to participate and comply with follow-up procedures&#xD;
&#xD;
          -  Good general health based on investigator's opinion&#xD;
&#xD;
          -  Ability to undergo surgery using general anaesthesia&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  RP, choroideremia, or rod cone dystrophy&#xD;
&#xD;
          -  Visual field less than 40 ° (if measurable)&#xD;
&#xD;
          -  Visual acuity not better than (1/50), (logMAR≥1.7)&#xD;
&#xD;
          -  Visual function stable for a duration of at least one year (according to subject&#xD;
             statement)&#xD;
&#xD;
          -  Normal eye pressure (9-21 mmHg)&#xD;
&#xD;
          -  Bulbus length (AP) between 21 and 25 mm&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Allergic response to multiple antibiotics&#xD;
&#xD;
          -  Known allergies to materials of the implant&#xD;
&#xD;
          -  Known carrier of multi-resistant organisms&#xD;
&#xD;
          -  Pregnancy or lactating&#xD;
&#xD;
          -  History of epileptic seizures&#xD;
&#xD;
          -  Having active implantable devices (or need within the next 3 years)&#xD;
&#xD;
          -  Patients with cancer or patients received cancer therapy within the last 2 years&#xD;
&#xD;
          -  Currently undergoing psychiatric treatment without expert opinion approving&#xD;
             participation on the study&#xD;
&#xD;
          -  Patients having insufficient mental capacity&#xD;
&#xD;
          -  Neurological diseases, in particular those affecting nerve conduction velocities&#xD;
&#xD;
          -  Patients currently taking medications affecting brain function&#xD;
&#xD;
          -  Immunosuppressive subjects&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gisbert Richard, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinik und Poliklinik für Augenheilkunde Hamburg-Eppendorf</affiliation>
  </overall_official>
  <removed_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </removed_countries>
  <reference>
    <citation>Hornig R, Laube T, Walter P, Velikay-Parel M, Bornfeld N, Feucht M, Akguel H, Rössler G, Alteheld N, Lütke Notarp D, Wyatt J, Richard G. A method and technical equipment for an acute human trial to evaluate retinal implant technology. J Neural Eng. 2005 Mar;2(1):S129-34. Epub 2005 Feb 22.</citation>
    <PMID>15876648</PMID>
  </reference>
  <verification_date>March 2010</verification_date>
  <study_first_submitted>January 25, 2007</study_first_submitted>
  <study_first_submitted_qc>January 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2007</study_first_posted>
  <last_update_submitted>March 2, 2010</last_update_submitted>
  <last_update_submitted_qc>March 2, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 3, 2010</last_update_posted>
  <responsible_party>
    <name_title>Intelligent Medical Implants GmbH</name_title>
    <organization>Medical device industry</organization>
  </responsible_party>
  <keyword>Visual Perception</keyword>
  <keyword>Retina</keyword>
  <keyword>Light</keyword>
  <keyword>Retinitis Pigmentosa</keyword>
  <keyword>Visual acuity</keyword>
  <keyword>Retinal Implant</keyword>
  <keyword>Electrical stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinitis</mesh_term>
    <mesh_term>Retinitis Pigmentosa</mesh_term>
    <mesh_term>Choroideremia</mesh_term>
    <mesh_term>Cone-Rod Dystrophies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

